Rotigotine transdermal system: a short review
Authors:
Open Access
- 1 December 2006
- journal article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 2 (4) , 421-426
Abstract
Rotigotine (Neupro((R))) is a new non-ergolinic dopamine agonist transdermal patch that can be applied once daily. To date, it is approved for the treatment of early Parkinson's disease as monotherapy and has been shown to be effective in the treatment of advanced-stage Parkinson's disease and restless legs syndrome in several clinical trials. This review gives an overview of physical, chemical, and pharmaceutical characteristics, pharmacokinetics, biotransformation and elimination, drug interactions, and adverse events of rotigotine. Further, the rationale for the treatment of Parkinson's disease and restless legs syndrome with rotigotine is discussed.Keywords
This publication has 19 references indexed in Scilit:
- Transdermal delivery of dopaminergic agentsNeurology, 2005
- A novel dopamine agonist for the transdermal treatment of Parkinson’s diseaseNeurology, 2005
- A promising new technology for Parkinson’s diseaseNeurology, 2005
- Role of Dopamine Receptor Agonists in the Treatment of Restless Legs SyndromeCNS Drugs, 2004
- Restless legs syndrome: diagnostic criteria, special considerations, and epidemiologySleep Medicine, 2003
- Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's DiseaseClinical Neuropharmacology, 2001
- Preventing levodopa-induced dyskinesias.2000
- Parkinson's disease: drug therapy.1997
- Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437European Journal of Pharmacology, 1989
- The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary resultsMovement Disorders, 1989